The event featured presentations from RedHill's management team who provided an overview of the Company's U.S. commercial strategy for launching Talicia® and Aemcolo®. RedHill’s expects to launch Aemcolo® in Q4/19 and Talicia® in Q1/20 with its expanding dedicated sales force.
For further information please contact: investors@redhillbio.com